Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.…
Mineralys stock gains after drug shows sustained blood pressure cuts
Mineralys Therapeutics (NASDAQ: MLYS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 76 employees.
The shares were at 13.66 USD on 20 November 2026, down 64.1% over 52 weeks. Its 52-week range is 13.57 USD to 47.65 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.21B USD.
Mineralys Therapeutics reports return on equity of -23.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 526.40M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 43.56 USD is 218.9% above the current price. The next earnings report is expected on 11 February 2027.